Medifast Management
Management Kriterienprüfungen 3/4
Medifast's CEO ist Dan Chard , ernannt in Oct 2016, hat eine Amtszeit von 7.67 Jahren. Die jährliche Gesamtvergütung beträgt $7.04M , bestehend aus 14.2% Gehalt und 85.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.46% der Aktien des Unternehmens, im Wert von $3.11M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.3 Jahre bzw. 7.7 Jahre.
Wichtige Informationen
Dan Chard
Geschäftsführender
US$7.0m
Gesamtvergütung
Prozentsatz des Geschäftsführergehalts | 14.2% |
Amtszeit als Geschäftsführer | 7.7yrs |
Eigentum des Geschäftsführers | 1.5% |
Durchschnittliche Amtszeit des Managements | 4.3yrs |
Durchschnittliche Amtszeit der Vorstandsmitglieder | 7.7yrs |
Jüngste Management Updates
Recent updates
Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good
Aug 21Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year
Aug 09Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?
Jul 27What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Jul 12Medifast And Its Real Value
Jun 24Medifast: Growth And Value At A Reasonable Price
May 17Analyse der Geschäftsführervergütung
Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
---|---|---|---|
Mar 31 2024 | n/a | n/a | US$68m |
Dec 31 2023 | US$7m | US$1m | US$99m |
Sep 30 2023 | n/a | n/a | US$120m |
Jun 30 2023 | n/a | n/a | US$133m |
Mar 31 2023 | n/a | n/a | US$142m |
Dec 31 2022 | US$6m | US$981k | US$144m |
Sep 30 2022 | n/a | n/a | US$151m |
Jun 30 2022 | n/a | n/a | US$157m |
Mar 31 2022 | n/a | n/a | US$165m |
Dec 31 2021 | US$7m | US$914k | US$164m |
Sep 30 2021 | n/a | n/a | US$158m |
Jun 30 2021 | n/a | n/a | US$150m |
Mar 31 2021 | n/a | n/a | US$125m |
Dec 31 2020 | US$6m | US$909k | US$103m |
Sep 30 2020 | n/a | n/a | US$95m |
Jun 30 2020 | n/a | n/a | US$76m |
Mar 31 2020 | n/a | n/a | US$76m |
Dec 31 2019 | US$5m | US$843k | US$78m |
Sep 30 2019 | n/a | n/a | US$74m |
Jun 30 2019 | n/a | n/a | US$72m |
Mar 31 2019 | n/a | n/a | US$64m |
Dec 31 2018 | US$2m | US$675k | US$56m |
Sep 30 2018 | n/a | n/a | US$47m |
Jun 30 2018 | n/a | n/a | US$40m |
Mar 31 2018 | n/a | n/a | US$34m |
Dec 31 2017 | US$2m | US$650k | US$28m |
Vergütung im Vergleich zum Markt: DanDie Gesamtvergütung ($USD7.04M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.58M).
Entschädigung vs. Einkommen: DanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Dan Chard (59 yo)
7.7yrs
Amtszeit
US$7,039,062
Vergütung
Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...
Führungsteam
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Executive Chairman & CEO | 7.7yrs | US$7.04m | 1.46% $ 3.3m | |
Chief Financial Officer | 3.9yrs | US$2.01m | 0.091% $ 206.0k | |
Chief Business Operations Officer | 2.4yrs | US$1.61m | 0.12% $ 263.4k | |
Executive VP | 12.6yrs | US$1.63m | 0.12% $ 262.3k | |
Chief Field Operations Officer | 5.3yrs | US$1.70m | 0.095% $ 214.5k | |
VP of Finance & Chief Accounting Officer | 2.8yrs | keine Daten | 0.0050% $ 11.2k | |
Vice President of Investor Relations | 1.3yrs | keine Daten | keine Daten | |
Chief Human Resources Officer | 4.7yrs | keine Daten | keine Daten |
4.3yrs
Durchschnittliche Betriebszugehörigkeit
53yo
Durchschnittliches Alter
Erfahrenes Management: MEDDas Führungsteam des Unternehmens gilt als erfahren (4.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Executive Chairman & CEO | 7.7yrs | US$7.04m | 1.46% $ 3.3m | |
Lead Independent Director | 9yrs | US$263.42k | 0.15% $ 329.4k | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Director | 6yrs | US$249.72k | 0.078% $ 176.9k | |
Independent Director | 5yrs | US$249.72k | 0.058% $ 132.1k | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Director | 6yrs | US$219.61k | keine Daten | |
Chairman of Scientific Advisory Board | 15.6yrs | keine Daten | keine Daten | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Director | 9yrs | US$252.44k | 0.073% $ 164.4k | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten |
7.7yrs
Durchschnittliche Betriebszugehörigkeit
62.5yo
Durchschnittliches Alter
Erfahrener Vorstand: MEDDie Vorstandsmitglieder gelten als erfahren (7.7 Jahre durchschnittliche Amtszeit).